# Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

> **NCT03012230** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Malignant Neoplasm in the Bone
- Stage IV Breast Cancer AJCC v6 and v7
- Triple-Negative Breast Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Ruxolitinib Phosphate

## Key facts

- **NCT ID:** NCT03012230
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-06
- **Primary completion:** 2023-01-06
- **Final completion:** 2023-03-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03012230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03012230, "Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03012230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*